As a leading global TCR company, Immunocore will focus on the development of ImmTAV and ImmTAB molecules for the treatment of tuberculosis (TB) and human immunodeficiency virus (HIV), which is expected to shorten treatment time and improve patient outcomes. 97 more words
Tags » HIV
Health experts in B.C. are examining an HIV prevention drug that a Vancouver gay men’s health group wants to see covered provincially.
The drug, called… 458 more words